$0.95
-0.04 (-4.51%)
Open$1.00
Previous Close$0.99
Day High$1.04
Day Low$0.92
52W High$28.27
52W Low$13.34
Volume—
Avg Volume642.4K
Market Cap8.57M
P/E Ratio45.23
EPS$0.55
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,852.2% upside
Current
$0.95
$0.95
Target
$27.91
$27.91
$22.75
$27.91 avg
$44.33
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.72M | 1.76M | 1.56M |
| Net Income | -70,204 | -56,960 | -48,803 |
| Profit Margin | -4.1% | -3.2% | -3.1% |
| EBITDA | -71,856 | -70,729 | -65,893 |
| Free Cash Flow | -27,215 | -37,098 | -32,467 |
| Rev Growth | -1.5% | +11.5% | -6.3% |
| Debt/Equity | 0.27 | 0.30 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |